Psyence Biomedical Ltd.
PBM
$1.76
$0.1811.39%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 91.54% | 97.00% | 101.98% | 17.62% | -1,018.12% |
| Total Depreciation and Amortization | 150.00% | 318.18% | 2,000.00% | 3,000.00% | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -99.88% | -104.58% | -108.84% | -18.28% | 103,504.63% |
| Change in Net Operating Assets | 64.92% | 66.06% | 67.08% | -547.77% | -169.75% |
| Cash from Operations | -47.85% | -37.18% | -26.78% | -18.46% | -9.15% |
| Capital Expenditure | 70.49% | 25.56% | -68.97% | -279.31% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -32,860.66% | -22,330.00% | -179.31% | -389.66% | -- |
| Total Debt Issued | -100.00% | -81.08% | -60.00% | 17.73% | 289.51% |
| Total Debt Repaid | -- | -- | -- | 0.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 753.78% | 1,269.38% | -- | 320.89% | -31.63% |
| Cash from Financing | 220.17% | 244.98% | 289.46% | 148.79% | 39.39% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 293.11% | 1,362.32% | 998.84% | 3,283.16% | 240.66% |